Portal de Periódicos da CAPES

Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa

2009; American Society of Clinical Oncology; Volume: 5; Issue: 2 Linguagem: Inglês

10.1200/jop.0922004

1935-469X

David Cella, Joseph C. Cappelleri, Andrew G. Bushmakin, Claudie Charbonneau, Jim Z. Li, Sindy T. Kim, Isan Chen, M. Dror Michaelson, Robert J. Motzer,

Multiple and Secondary Primary Cancers

In a randomized phase III trial, sunitinib was associated with significantly superior progression-free survival when compared with interferon alfa as first-line therapy in patients with metastatic renal cell carcinoma. This article investigates whether baseline quality of life and demographic and clinical variables were predictive for progression-free survival.